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5-Lipoxygenase inhibitor and human recombinant erythropoietin might accelerate
renal recovery in cisplatin-induced acute renal failure rats. Male Sprague-Dawley rats
were randomized into four groups: 1) normal controls; 2) Cisplatin group-cisplatin
induced acute renal failure (ARF) plus vehicle treatment; 3) Cisplatin+nordihydrogua-
iaretic acid (NDGA) group-cisplatin induced ARF plus 5-lipoxygenase inhibitor treat-
ment; 4) Cisplatin+erythropoietin (EPO) group-cisplatin induced ARF plus erythro-
poietin treatment. On day 10 (after 7 daily injections of NDGA or EPO), urea nitro-
gen and serum Cr concentrations were significantly lower in the Cisplatin+NDGA
and Cisplatin+EPO groups than in the Cisplatin group, and 24 hr urine Cr clearances
were significantly higher in the Cisplatin+EPO group than in the Cisplatin group. Semi-
quantitative assessments of histological lesions did not produce any significant dif-
ferences between the three treatment groups. Numbers of PCNA(+) cells were sig-
nificantly higher in Cisplatin, Cisplatin+NDGA, and Cisplatin+EPO groups than in
normal controls. Those PCNA(+) cells were significantly increased in Cisplatin+NDGA
group. These results suggest that EPO and also NDGA accelerate renal function
recovery by stimulating tubular epithelial cell regeneration.
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INTRODUCTION
Acute renal failure (ARF) is characterized by a rapid decline
in glomerular filtration rate (GFR) over hours to days, and
the retentions of nitrogenous waste products. The mortality
rate of patients with ARF has remained 25-70% despite the
use of various pharmacologic agents (1). Therefore, a new
therapeutic agent is required to promote renal function recov-
ery and a noninvasive early biomarker is needed to determine
the presence of early ARF.
The anticancer drug cisplatin is one of the most active drugs
used to treat tumors (2, 3). Furthermore, cisplatin may induce
injury to renal tubular epithelial cells and subsequent renal
failure (4). 
Bagnis et al. (5) reported that human recombinant erythro-
poietin (EPO) enhances recovery from cisplatin-induced ARF
in the rats, which suggests that EPO acts directly on dam-
aged tubular cells and stimulates their regeneration. EPO is
a cytokine that is produced primarily in the kidneys (6), and
which regulates the differentiation and proliferation of ery-
throid progenitor cells. However, its effects may not be lim-
ited to bone marrow progenitor cells, because in vitro, human
recombinant EPO stimulates endothelial cell proliferation
(7) and angiogenesis (8).
The 5-lipoxygenase (LOX) inhibitor, nordihydroguaiaret-
ic acid (NDGA), is a simple lignin and is found in evergreen
shrubs, such as the creosote bush (Larrea tridentata or Larrea
divarita), which has a worldwide distribution. The creosote
bush is used in traditional medicine to treat more than 50
illnesses, such as rheumatism, diabetes, sterility, gallbladder
and kidney stones (9-15). Furthermore, LOX inhibitors have
been reported to have protective effects on ileal motor dis-
turbances induced by endotoxins (16), to promote adapta-
tion following massive bowel resection (17), and to aid the
correction of coronary spasms of immune origin (18). 
Most studies reported previously, were designed to admin-
ister drugs before or at the same time of renal insult. How-
ever, most therapeutic agents are usually administered after
the expression of clinical diseases. Therefore we hypothesized
that EPO and NDGA might affect the course of tubular repair
after the onset of cisplatin-induced ARF, and thus, acceler-
ate renal recovery in the rats. 
MATERIALS AND METHODS
Drugs and reagents
Cisplatin (Cisplan
�, Dong-A Pharm., Seoul, Korea) was
provided as a powder dissolved in saline (1 mg/mL). Human
recombinant EPO (Epoetin beta; Recormon
�, Roche, Switzer-
land) was provided as a 2,000 IU/mL solution. The 5-LOX
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inhibitor, NDGA (6-dimethylamino-9 [3′ amino-3′ deoxy-
ribosyl] purine, Sigma Chemical Co., St. Louis, MO, U.S.A.)
was provided as a powder dissolved in dimethyl sulfoxide
(DMSO) solution.
Animals
Male Sprague-Dawley rats (n=40), initially weighing 200-
250 g were kept in individual metabolic cages with free access
to standard chow and water. The rats were divided into four
groups: 1) the normal control group (n=10); 2) the Cisplatin
group (n=10)-Cisplatin induced ARF plus vehicle; 3) the
Cisplatin+NDGA group (n=10)-Cisplatin induced ARF
plus NDGA; 4) the Cisplatin+EPO group (n=10)-Cisplatin
induced ARF plus EPO. Animals were clinically investigat-
ed and subjected to standard laboratory tests for one week
before being sacrificed for kidney removal. All experiments
were performed in accordance with the National Institute’s
of Health ‘Guiding Principles for the Care and Use of Laboratory
Animals’.
Treatment schedule
On day 1, ARF was provoked by a single intraperitoneal
(i.p.) injection (6 mg/kg body weight) in the Cisplatin, Cis-
platin+NDGA, and Cisplatin+EPO groups. Control rats
received an identical volume of normal saline.
On day 4, serum and 24 hr urine samples were obtained to
confirm the onset of ARF. After induction of ARF, rats were
treated with vehicle, NDGA, or EPO from day 4 to 10 as fol-
lows; the 10 rats in the Cisplatin+NDGA group were injected
daily with NDGA (10 mg/kg/day; s.c.), the 10 rats in the
Cisplatin+EPO group with EPO (100 IU/kg/day; s.c.), the
10 rats in the Cisplatin group and the 10 rats in the control
group were also injected s.c. with vehicle (volumes equiva-
lent to the NDGA injections). 
On days 1, 4, and 10, serum and 24 hr urine samples were
collected to determine biochemical parameters. Serum sam-
ples were obtained from the retro-orbital plexus to measure
hemoglobin (Hb), hematocrit (Hct), urea nitrogen (BUN),
creatinine (SCr), sodium (Na), and potassium (K). Twenty four-
hour urine samples were collected in metabolic cages to deter-
mine urine volumes, and urea nitrogen, Cr, Na, and K levels.
Twenty four-hour urine Cr clearances (CCr) were viewed as
surrogates of GFR.
Histological examination
On day 10, all rats were sacrificed by injecting ketamine
(i.p.) under general anesthesia. Rats were perfused through
left ventricles with saline and kidneys were removed imme-
diately for histological examinations. Semi-quantitative analy-
sis was performed on kidney sections in a blind manner. Tubu-
lar lesions were graded as follows (5): 0=no damage; 1+=areas
of tubular epithelial cell swelling, vacuolization, necrosis,
and desquamation <50%; 2+=lesion areas >50% with or
without focal involvement of the S3 segment of medullary
rays; 3+=lesion areas 100% with diffuse involvement of
medullary rays. Immunostaining for proliferating cell nucle-
ar antigen (PCNA) was performed using the ABC procedure
(5). Kidneys were fixed in 15% formalin overnight, ethanol
dehydrated, and paraffin embedded. Sections were then incu-
bated for 3×5 min in a microwave oven for PCNA labeling,
for 5 min with goat non-immune serum to reduce non-spe-
cific background staining, and for 1 hr at room temperature
with specific antibody diluted in 10% goat serum. After a
10-min rinse in PBS, sections were incubated for 10 min at
room temperature with a biotinylated goat anti-mouse IgG
antibody, treated with avidin-biotin-peroxidase complex,
and then with 3,3′ diaminobezidine. The sections were coun-
terstained with hematoxylin and mounted in Eukit. Each
tissue sample stained for PCNA was viewed and scored by a
pathologist blinded to the treatment received. Quantifica-
tion of tubular cells was performed with an image analyzer
computer system (Cambridge Instrument Q250 Rueil Mal-
maison, France) on 20 fields (area field: 0.109 mm2) outside
the glomerular area. Renal tissue samples were divided into
cortical and cortico-medullary area for quantification of stain-
ing (5). 
Statistical analyses
All values are presented as means±SD. Two-way ANOVA
and post-hoc analysis (Tukey test) were used throughout. Sta-
tistical significance was accepted for pvalues of <0.05.
RESULTS
Induction of ARF
On day 1, no significant differences were evident between
the four groups in terms of body weight, serum Hb, BUN,
SCr, 24 hr urine volume, Na and CCr (Table 1).
On day 4 (three days after injecting of cisplatin), rats in
the Cisplatin, Cisplatin+NDGA, and Cisplatin+EPO groups
lost weight (203.0±2.8 to 176.0±25.4, 206.0±5.5 to
168.0±5.7, and 203.0±2.7 to 169.0±6.5 g, respective-
ly), whereas rats in the control group gained weight (203.0
±2.7 to 226.0±6.5 g) (p<0.05). Mean serum BUN of the
Cisplatin, Cisplatin+NDGA, and Cisplatin+EPO groups
(the three treatment groups) were significantly higher (154.6
±60.1, 209.6±35.0, and 155.8±43.7 mg/dL, respective-
ly) than that of the control group (12.6±1.9 mg/dL) (p<
0.05). Mean SCr of the three treatment groups were also sig-
nificantly higher (2.0±0.7, 1.7±0.3, and 1.8±0.4 mg/dL,
respectively) than that of the control group (0.4±0.1 mg/dL)
(p<0.05). However, CCr were significantly lower in the threeS172 D.W. Lee, I.S. Kwak, S.B. Lee, et al.
treatment groups (0.11±0.05, 0.12±0.10, and 0.21±0.07
mL/min, respectively) than in the control group (1.30±0.24
mL/min) (p<0.05), as were 24 hr urine Na concentrations
(UNa) (37.4±17.5, 58.9±11.2, and 65.4±29.1 mL/min,
respectively, vs. 135.8±5.2 mEq/L) (p<0.05). On the other
hand, fractional excretions of Na (FENa) in the three treatment
groups were significantly higher (3.3±3.8, 6.8±5.7, 3.7±
1.5%, respectively) than in the control group (0.5±0.1%)
(p<0.05), as were renal failure indices (RFI) (4.6±5.2, 9.3
±7.6, and 5.1±2.1, respectively, vs. 0.7±0.1) (p<0.05)
(Table 1).
Effects of NDGA and EPO on renal function recovery
On day 10 (after 7 daily injections of NDGA or EPO),
controls gained weight (226.0±6.5 to 242.0±9.8 g), where-
as Cisplatin group rats lost weight (176.0±25.4 to 172.0±
10.9 g). Cisplatin+NDGA and Cisplatin+EPO groups were
significantly heavier than Cisplatin group (217±12.0, and
188.0±7.6, respectively, vs. 172.0±10.9 g) (p<0.05).
On day 10, serum Hb levels in the Cisplatin+EPO group
were significantly higher than in the Cisplatin and Cisplatin+
NDGA groups (15.7±0.4 vs. 14.0±0.3 and 13.7±0.3
g/dL, respectively) (both p<0.05 vs. Cisplatin and Cisplatin+
NDGA group).
Normal
controls
Day Cisplatin
Cisplatin+
NDGA
Cisplatin+
EPO
Body 1 203.0±2.7 203.0±2.8 206.0±5.5 203.0±2.7
weight (g) 4 226.0±6.5 176.0±25.4 168.0±5.7 169.0±6.5
Serum Hb  1 14.5±0.7 14.2±0.5 14.2±0.7 14.3±0.5
(g/dL) 4 14.3±0.5 13.8±0.2 13.9±0.1 13.8±0.2
Serum BUN  1 15.2±2.9 19.4±3.9 18.8±2.9 18.3±3.8
(mg/dL) 4 12.6±1.9 154.6±60.1 209.6±35.0 155.8±43.7
SerumCr 1 0.6±0.0 0.4±0.1 0.5±0.1 0.5±0.1
(mg/dL) 4 0.4±0.1 2.0±0.7 1.7±0.3 1.8±0.4
24 hr urine Cr 1 1.04±0.10 1.17±0.29 1.14±0.16 1.18±0.55
clearance 4 1.30±0.24 0.11±0.05 0.12±0.10 0.21±0.07
(mL/min)
24 hr urine Na1 131.4±9.7 148.9±24.6 128.5±17.3 149.3±24.3
(mEq/L) 4 135.8±5.2 37.4±17.5 58.9±11.2 65.4±29.1
FENa, (%) 1 0.6±0.0 0.7±0.2 0.7±0.1 0.8±0.4
4 0.5±0.1 3.3±3.8 6.8±5.7 3.7±1.5
Renal failure  1 0.8±0.0 1.0±0.3 1.0±0.1 1.1±0.6
index 4 0.7±0.1 4.6±5.2 9.3±7.6 5.1±2.1
Table 1. Basal parameters before and after induction of acute
renal failure in the four experimental groups
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Fig. 1. Changes of mean serum and 24 hr urine parameters in the four groups. (A) Significant reductions in BUN levels were observed in
the Cisplatin+NDGA and Cisplatin+EPO groups between Day 4 and Day 10. (B) Significant serum creatinine decreases were observed
in the Cisplatin+NDGA and Cisplatin+EPO groups between Day-4 and Day-10. (C) Significant creatinine clearance increases were observed
in the Cisplatin+EPO group between Day-4 and Day-10. (D) Significant Na concentration increases in urine were observed in the Cisplatin+
NDGA group between Day-4 and Day-10. *p<0.05 vs. Cisplatin group. Normal controls (dashed line,    ), Cisplatin (   ), Cisplatin+NDGA
(    ), Cisplatin+ EPO (    ). 
A
M
e
a
n
 
s
e
r
u
m
 
C
r
 
(
m
g
/
d
L
)
2.5
2.0
1.5
1.0
0.5
14 1 0
Day B
M
e
a
n
 
C
r
 
c
l
e
a
r
a
n
c
e
 
(
m
L
/
m
i
n
)
1.5
1.0
0.5
14 1 0
Day C
M
e
a
n
 
u
r
i
n
e
 
N
a
 
(
m
E
q
/
L
)
150
100
50
14 1 0
Day D
�
*
*
* *
NDGA, nordihydroguaiaretic acid; EPO, erythropoietin; BUN, blood
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On day 10, BUN concentrations in the Cisplatin+NDGA
group were significantly decreased from day 4 (209.6±35.0
to 22.6±10.5 mg/dL) (p<0.05 vs. Cisplatin group). Simi-
larly, BUN in the Cisplatin+EPO group were significantly
decreased from day 4 (155.8±43.7 to 27.8±3.8 mg/dL)
(p<0.05 vs. Cisplatin group) (Fig. 1A). SCr in the Cisplatin+
NDGA and Cisplatin+EPO groups were also significantly
decreased from day 4 (1.7±0.3 to 1.2±0.5, and 1.8±0.4
to 0.8±0.2 mg/dL, respectively) (both p<0.05 vs. Cisplatin
group) (Fig. 1B). CCr in the Cisplatin+EPO group on day
10 recovered significantly from day 4 (0.21±0.07 to 0.94±
0.49 mL/min) (p<0.05 vs. Cisplatin group). However, the
Cisplatin+NDGA group showed only a tendency to recover
(0.12±0.10 to 0.32±0.25 mL/min) (p>0.05) (Fig. 1C).
UNa in the Cisplatin+NDGA group on day 10 were signif-
icantly increased from day 4 (58.9±11.2 to 78.7±10.6
mEq/L) (p<0.05 vs. Cisplatin group), but this was not the
case in the Cisplatin+EPO group (Fig. 1D). FENa and RFI
values in the Cisplatin+NDGA and Cisplatin+EPO groups
showed a tendency to diminish from day 4 to day 10 (p>0.05).
Effects of NDGA and EPO on renal histology
All rats in the three treatment groups showed structural
damage, although glomeruli and vessels were normal. Changes
were limited to tubules, usually the proximal straight S3 por-
tion in the outer medulla. Semi-quantitative assessments of
histological lesions produced significantly higher scores for
the three treatment groups than the normal controls at day
10. However, no significant differences were observed between
the three treatment groups (Table 2, Fig. 2). Numbers of
PCNA-positive cells were significantly higher in the corti-
Normal
controls
Cisplatin
Cisplatin+
NDGA
Cisplatin+
EPO
Total number n=10 n=10 n=10 n=10
01 0 0 1 2
1+ 0 1 4 2
2+ 0 3 3 5
3+ 0 6 2 1
Table 2. Semi-quantitative evaluation of historical lesions at day 10
0=no damage; 1+=area of tubular epithelial cell swelling, vacuolization,
necrosis, desquamation of <50%; 2+=lesion areas >50% with or with-
out focal involvement of the S3 segment in the medullary rays; 3+=lesion
areas 100% with diffuse involvement of medullary rays. 
NDGA, nordihydroguaiaretic acid; EPO, erythropoietin; BUN, blood
urea nitrogen.
Normal
controls
Cisplatin
Cisplatin+
NDGA
Cisplatin+
EPO
Cortical area 1389±185 1986±154* 2276±245*,� 2012±203*
Cortico- 1165±105 2078±177* 2763±213*,� 2145±198*
medullary area
Table 3. Numbers of tubular cell nuclei stained with proliferating
cell nuclear antigen (PCNA) in the cortical and cortico-medullary
areas at day 10
*p<0.05 vs. normal controls; 
� p<0.05 vs. Cisplatin group. 
NDGA, nordihydroguaiaretic acid; EPO, erythropoietin; BUN, blood
urea nitrogen.
Fig. 2. Histological aspects of the rat corticomedullary junction 10
days after cisplatin administration showing tubular epithelial cell
swelling, vacuolization, necrosis, and desquamation affecting pri-
marily the proximal tubule. NDGA and EPO did not modify the
effects of cisplatin on renal histology (×400, PAS).
Fig. 3. PCNA-positive cells in Cisplatin+NDGA group. PCNA stain-
ing showing large nuclei of regenerating cells on day 10 (×400).S174 D.W. Lee, I.S. Kwak, S.B. Lee, et al.
cal and cortico-medullary areas of kidneys in the Cisplatin,
Cisplatin+NDGA and Cisplatin+EPO groups than in the
normal controls. After treatments of NDGA, the number of
PCNA-positive cells was significantly higher than in the Cis-
platin group. However, no significant difference was observed
in the Cisplatin+EPO group (Table 3, Fig. 3).
DISCUSSION
Cisplatin is widely known to induce ARF as a result of renal
tubular epithelial cell injury. This cytotoxicity is considered
to be due to several factors, e.g., the peroxidation of cell mem-
branes, mitochondrial dysfunction, inhibition of protein syn-
thesis, and DNA damage (19-22). Cisplatin accumulates in
renal tubular cells to a concentration approximately five times
higher than its extracellular concentration, and this uptake
is most prominent in the S3 segment of proximal tubules.
Experimental prevention of cisplatin-induced ARF has been
achieved by intensive hydration (mainly with chloride con-
taining salts) and by administering diuretics (23-25). 
Recently, several researchers have suggested that human
recombinant EPO might enhance recovery from cisplatin-
induced ARF or ischemic injury in the rats. The data pre-
sented suggest that EPO accelerates renal recovery by induc-
ing hemodynamic improvements and by stimulating tubu-
lar cell regeneration (5, 26). EPO is a cytokine that specifi-
cally regulates the differentiation and proliferation of erythroid
progenitor cells, and the proliferating effect of EPO has also
been demonstrated in other types of cells, like endothelial
cells (7), which also possess an EPO receptor (27, 28). Fur-
thermore, the expressions of specific high-affinity EPO bind-
ing sites have been demonstrated in rat and mouse megakary-
ocytes (29), which explain why platelet counts increase in
patients on high dose EPO (30). Furthermore, tubular and
mesangial cells also express EPO receptor mRNA (31), which
suggests that EPO acts as a renotropic cytokine.
NDGA is a potent inhibitor of lipoxygenase activity and
a strong antioxidant. It has been reported to reduce protein-
uria and systolic blood pressure in diabetic rats, possibly via
hemodynamic improvements induced, at least in part, by
the maintenance of glutathione (GSH; an antioxidant enzyme)
levels by NDGA within normal physiologic limits (32). In
addition, NDGA is reported to protect ileal motor distur-
bances (16), to promote bowel adaptation (17), and to con-
trol coronary spasms of immune origin (18). Therefore we
expected that NDGA might have regenerative and immu-
nomodulating properties similar to EPO.
In the present study, we assessed the effects of NDGA and
EPO on rapid renal recovery of cisplatin-induced ARF. Both
EPO and NDGA were found to have a renoprotective effect
and to accelerate the recovery of damaged renal tubular epithe-
lial cells. EPO was found to accelerate renal recovery, which
is in accordance with the results of previous studies. How-
ever, these indices may also have been affected by hemody-
namic improvements due to the correction of anemia. NDGA
also decreased BUN and SCr, and increased UNa significant-
ly. In addition, NDGA also enhanced renal function without
affecting Hb levels. PCNA is an auxiliary protein to DNA
polymerase δ , and it is expressed in nucleus strongly in late
G1 and S phases of the cell cycle. Therefore PCNA antibod-
ies are used as tools for detecting proliferating cells. The pre-
sent study showed more increased PCNA-positive cells in
the Cisplatin+NDGA group than in the Cisplatin group,
and also showed a tendency to increase in the Cisplatin+EPO
group. These results suggest that NDGA might act directly
via stimulation of tubular cell regeneration even in the set-
ting of post-treatment.
The management of acute tubular necrosis still hinges on
the prevention and treatment of uremic complications until
renal function spontaneously recovers. A number of agents
have been investigated to determine whether they can atten-
uate injury or hasten recovery in ischemic and nephrotoxic
acute tubular necrosis, but unfortunately, no agent has been
found to reduce the incidence of acute tubular necrosis or to
reduce dialysis requirements or mortality. 
The present study suggests that EPO and also NDGA may
accelerate renal function recovery by stimulating tubular
epithelial cell regeneration even after clinical onset of ARF.
Furthermore, our findings indicate that NDGA has thera-
peutic potential, which we consider warrants further inves-
tigation in man.
REFERENCES
1. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl
J Med 1996; 334: 1448-60.
2. Loehrer PJ, Einhorn LH. Drugs five years later. Cisplatin. Ann Intern
Med 1984; 100: 704-13.
3. Dillman RO, Seagren SL, Propert KJ, Guerra J, Eaton WL, Perry
MC, Carey RW, Frei EF 3rd, Green MR. A randomized trial of
induction chemotherapy plus high dose radiation versus radiation
alone in stage III non-small cell lung cancer. N Engl J Med 1990;
323: 940-5.
4. Blachley JD, Hill JB. Renal and electrolyte disturbances associated
with cisplatin. Ann Intern Med 1981; 95: 628-32.
5. Bagnis C, Beaufils H, Jacquiaud C, Adabra Y, Jouanneau C, Le
Nahour G, Jaudon MC, Bourbouze R, Jacobs C, Deray G. Erythro-
poietin enhances recovery after cisplatin-induced acute renal fail-
ure in the rat. Nephrol Dial Transplant 2001; 16: 932-8.
6. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney
in erythropoiesis. Nature 1957; 179: 633-4.
7. Nagai T, Akizawa T, Nakashima Y, Kohjiro S, Nabeshima K, Kana-
mori N, Takayama K, Kinugasa E, Koshikawa S. Effects of rHuEpo
on cellular proliferation and endothelin-1 production in cultured
endothelial cells. Nephrol Dial Transplant 1995; 10: 1814-9.
8. Carlini RG, Reyes AA, Rothstein M. Recombinant human erythro-EPO and NDGA on Cisplatin-induced ARF Rat S175
poietin stimulates angiogenesis in vitro. Kidney Int 1995; 47: 740-5.
9. Mabry TJ, Hunzinker JH, DiFeo DR. Creosote bush. Biology and
chemistry of Larrea in new world deserts. Stroudsburg, Pa: Dowden,
Hutchinson & Ross 1979.
10. Brinker F. Larrea tridentata (DC) Coville (chaparral or creosote
bush). Br J Phytotherapy 1993; 3: 10-31.
11. Argueta A, Gallardo Vazquez MC. Atlas of the Traditional Mexican
Medicinal Plants (vol II). Mexico: National Indigenous Institute 1994;
669-70.
12. Foster S, Tyler VE. Tyler’s Honest Herbal: a sensible guide to the
use of herbs and related remedies. New York: Haworth Herbal Press
1999; 109-11.
13. Winkelman M. Ethnobotanical treatments of diabetes in Baja Cali-
fornia Norte. Med Anthropol 1989; 11: 255-68. 
14. Lara F, Marquez C. Medicinal plants from Mexico: composition,
uses and biological activity. UNAM, Mexico 1996; 9-61.
15. Brent J. Three new herbal hepatotoxic syndromes. J Toxicol Clin
Toxicol 1999; 37: 715-9. 
16. Ezberci F, Tekin E, Onuk E. Protective effect of a lipoxygenase in-
hibitor, nordihydroguaiaretic acid, on the ileal motor disturbances
induced by Serratia marcescens endotoxin in rats. Surg Today 2001;
31: 497-501.
17. Kollman-Bauerly KA, Thomas DL, Adrian TE, Lien EL, Vander-
hoof JA. The role of eicosanoids in the process of adaptation follow-
ing massive bowel resection in the rat. JPEN J Parenter Enteral Nutr
2001; 25: 275-81.
18. Marchenko HI, Kotsiuruba VM, Butovych IA, Sorochynskyi AE,
Zrazhevska VK, Tumanovska LV. The correction of disorders in
arachidonic acid metabolism in coronary spasm of an immune ori-
gin. Fiziol Zh 1994; 40: 81-7.
19. Sugiyama S, Hayakawa M, Kato T, Hanaki Y, Shimizu K, Ozawa
T. Adverse effects of anti-cancer drug, cisplatin on rat kidney mito-
chondria: disturbances in glutathione peroxidase activity. Biochem
Biophys Res Commun 1989; 159: 1121-7.
20. Brady HR, Kone BC, Stromski ME, Zeidel ML, Giebisch G, Gullans
SR. Mitochondrial injury: an early event in cisplatin toxicity to renal
proximal tubules. Am J Physiol Renal Fluid Electrolyte Physiol 1990;
258: F1181-7. 
21. Leibbrandt ME, Wolfgang GH, Metz AL, Ozobia AA, Haskins JR.
Critical subcellular targets of cisplatin and related platinum analogs
in renal proximal tubule cells. Kidney Int 1995; 48: 761-70.
22. Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichsel-
baum RR, Kufe DW. Activation of the c-Abl tyrosine kinase in the
stress response to DNA-damaging agents. Nature 1995; 376: 785-8.
23. Heidemann TH, Gerkens JF, Jackson EK, Branch RA. Attenuation
of cisplatinum-induced nephrotoxicity in the rat by high salt diet,
furosemide and acetazolamide. Naunyn Schmiedebergs Arch Phar-
macol 1985; 329: 201-5. 
24. Daley-Yates PT, McBrien DC. A study of the protective effect of chlo-
ride salts on cisplatin nephrotoxicity. Biochem Pharmacol 1985; 34:
2363-9.
25. Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Im-
provement of Cis-dichlorodiamineplatinum (NCS 119875): thera-
peutic index in an animal model. Cancer 1977; 39: 1357-61.
26. Nemoto T, Yokota N, Keane WF, Rabb H. Recombinant erythropoi-
etin rapidly treats anemia in ischemic acute renal failure. Kidney
Int 2001; 59: 246-51. 
27. Anagnostou A, Lee ES, Kessimian N, Levinson R, Steiner M. Ery-
thropoietin has a mitogenic effect and a positive chemotactic effect
on endothelial cells. Proc Natl Acad Sci USA 1990; 87: 5978-82.
28. Anagnostou A, Liu Z, Steiner M, Chin K, Lee ES, Kessimian N,
Noguchi CT. Erythropoietin receptor mRNA expression in human
endothelial cells. Proc Natl Acad Sci USA 1994; 91: 3974-8. 
29. Fraser JK, Tan AS, Lin FK, Berridge MV. Expression of specific
high-affinity binding sites for erythropoietin on rat and mouse mega-
karyocytes. Exp Hematol 1989; 17: 10-6.
30. Kitagawa S, Masaki S, Miura Y. Recombinant human erythropoietin
at high doses stimulates thrombopoiesis: treatment for protracted
severe myelosuppression complicating interferon-alpha and busul-
fan therapy for chronic myelogenous leukemia. Eur J Haematol 1995;
55: 285-6.
31. Westenfelder C. Tubular and mesangial cells of human, rat and mouse
kidney express authentic erythropoietin receptor mRNA. Nephrolo-
gy 1997; S22. 
32. Anjaneyulu M, Chopra K. Nordihydroguairetic acid, a lignin, pre-
vents oxidative stress and the development of diabetic nephropathy
in rats. Pharmacology 2004; 72: 42-50.